These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 9809994)

  • 1. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern.
    Nooijen PT; Eggermont AM; Schalkwijk L; Henzen-Logmans S; de Waal RM; Ruiter DJ
    Cancer Res; 1998 Nov; 58(21):4880-7. PubMed ID: 9809994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolated limb perfusion for unresectable melanoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
    Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
    Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
    Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
    Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
    Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion.
    Di Filippo F; Giacomini P; Rossi CR; Santinami M; Anzà M; Garinei R; Perri P; Botti C; Di Angelo P; Sofra C; Pasqualoni R; Sperduti I; Cavaliere F; Di Filippo S; Corrias F; Armenti A; Ferraresi V; Ginebri A
    In Vivo; 2009; 23(2):347-52. PubMed ID: 19414425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan.
    Vaglini M; Santinami M; Manzi R; Inglese MG; Santoro N; Persiani L; Belli F
    Melanoma Res; 1994 Mar; 4 Suppl 1():35-8. PubMed ID: 8038594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
    Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
    J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan.
    Bauer TW; Gutierrez M; Dudrick DJ; Li J; Blair IA; Menon C; Fraker DL
    Surgery; 2003 Apr; 133(4):420-8. PubMed ID: 12717360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma].
    Kettelhack C; Hohenberger P; Schlag PM
    Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis.
    Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S
    In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha.
    Laurenzi L; Natoli S; Di Filippo F; Calamaro A; Centulio F; Anzà M; Cavaliere F; Marcelli ME; Garinei R; Arcuri E
    J Exp Clin Cancer Res; 2004 Jun; 23(2):225-31. PubMed ID: 15354406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.
    Fraker DL; Alexander HR; Andrich M; Rosenberg SA
    Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response.
    Hoving S; Seynhaeve AL; van Tiel ST; aan de Wiel-Ambagtsheer G; de Bruijn EA; Eggermont AM; ten Hagen TL
    Anticancer Drugs; 2006 Sep; 17(8):949-59. PubMed ID: 16940805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
    Kettelhack C; Hohenberger P; Schlag PM
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study.
    Liénard D; Eggermont AM; Schraffordt Koops H; Kroon BB; Rosenkaimer F; Autier P; Lejeune FJ
    Melanoma Res; 1994 Mar; 4 Suppl 1():21-6. PubMed ID: 8038591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.
    Posner MC; Lienard D; Lejeune FJ; Rosenfelder D; Kirkwood J
    Cancer J Sci Am; 1995; 1(4):274-80. PubMed ID: 9166488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.